NeuroSense granted U.S. patent for PrimeC in ALS

NeuroSense announced the issuance of a pivotal patent by the USPTO relating to the novel formulation of PrimeC, NeuroSense’s leading drug candidate for the treatment of Amyotrophic Lateral Sclerosis – ALS -. This patent is expected to extend PrimeC’s patent protection by an additional four years, until 2042. The patent grant follows NeuroSense’s recent clinical findings, where PrimeC demonstrated a 36% reduction in disease progression (p=0.009) and a 43% improvement in survival rates compared to placebo, underscoring its potential as a breakthrough therapy for ALS.